NASDAQ$GENB

Generate Biomedicines, Inc · Q1 2026 earnings

Q1 2026 earnings ·

Briefing

Generate Biomedicines reported Q1 2026 collaboration revenue of $7.2M and a net loss of $61.7M ($1.07 per share).

Q1 2026 collaboration revenue was $7.2 million versus $8.8 million. Operating expenses were $71.3 million; net loss was $61.7 million ($1.07 per share) versus $44.3 million. The company completed its IPO in March 2026 and a reverse stock split in February 2026.

  • Collaboration revenue $7.2M vs $8.8M.
  • Net loss $(61.7)M; EPS $(1.07).
  • R&D $57.8M on generative biology platform.
  • March 2026 IPO completed.
  • Pre-commercial stage with partnership funding.

Headline financials

Total Revenue

$7.22M

No prior period
EPS (adj)

-$1.07

No prior period
Capital Expenditures

-$3.78M

No prior period
Free Cash Flow

-$84.2M

No prior period
Net Income

-$61.4M

No prior period
Operating Income

-$64.1M

No prior period
Cash & Equivalents

$161M

No prior period
Total Assets

$626M

No prior period

Revenue & EPS history

Generate Biomedicines, Inc · Revenue · Quarterly

$7.22M

Q1 2026
Beat estimate in 1 of 1 quarters(100%)
ActualEstimate

Forward guidance

Post-IPO filings focus on platform partnerships, pipeline milestones, and cash runway rather than revenue guidance.

Tailwinds

  • Fresh public-market capital from IPO.
  • Collaboration revenue provides non-dilutive funding.

Headwinds

  • Widening loss on R&D scale-up.
  • No product revenue yet.

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro